PAN Provides Co-payment Assistance for Patients with Myeloproliferative Neoplasms (MF, PV, ET)
WASHINGTON, D.C., November 17, 2011– Patient Access Network (PAN) Foundation is pleased to announce that it has begun providing co-payment assistance to under-insured patients with Myeloproliferative Neoplasms. The covered conditions include Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Myelofibrosis (MF). Qualified patients will be granted up to $7,500 per year to cover out-of-pocket expenses associated with their treatment. Patients who earn up to 500% of the Federal Poverty Level, or $73,550 for a family of two, are eligible for assistance.
"We are optimistic about the development of new therapies that treat patients with Myeloproliferative Neoplasms," said Pat McKercher, President of Patient Access Network Foundation. "We are hopeful that with our assistance patients will have access to these progressive treatments that more effectively treat these serious diseases."
Myeloproliferative Neoplasms (MPNs) are types of blood cancer that begin with an abnormal mutation (change) in a stem cell in the bone marrow. The change leads to an overproduction of any combination of white cells, red cells and platelets. The three main Myeloproliferative Neoplasms are Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Myelofibrosis (MF). More information about these conditions can be found on the National Cancer Institute's website www.cancer.gov.
This new fund is an expansion of PAN’s 35 existing disease funds that cover conditions such as multiple myeloma, colorectal cancer, and rheumatoid arthritis. PAN provides grants of $1,500 to $15,000 per year to qualified patients to help pay for medications for these diseases. Since 2004, PAN has provided more than $173 million in assistance for out-of-pocket expenses to more than 125,000 patients in need. For more information about the Patient Access Network Foundation, visit www.PANfoundation.org.